Metabolic barriers to cancer immunotherapy

被引:336
|
作者
DePeaux, Kristin [1 ,2 ]
Delgoffe, Greg M. [1 ,2 ]
机构
[1] UPMC Hillman Canc Ctr, Tumor Microenvironm Ctr, Pittsburgh, PA 15232 USA
[2] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA
关键词
CD8(+) T-CELLS; MEMORY STEM-CELLS; B-CELL; AEROBIC GLYCOLYSIS; CRITICAL REGULATOR; IMMUNE RESISTANCE; RECEPTOR PD-1; ION CHANNELS; CHECKPOINT; CTLA-4;
D O I
10.1038/s41577-021-00541-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several non-redundant features of the tumour microenvironment facilitate immunosuppression and limit anticancer immune responses. These include physical barriers to immune infiltration, the recruitment of suppressive immune cells and the upregulation of ligands on tumour cells that bind to inhibitory receptors on immune cells. Recent insights into the importance of the metabolic restrictions imposed by the tumour microenvironment on antitumour T cells have begun to inform immunotherapeutic anticancer strategies. Therapeutics that target metabolic restrictions, such as low glucose levels, a low pH, hypoxia and the generation of suppressive metabolites, have shown promise as combination therapies for different types of cancer. In this Review, we discuss the metabolic aspects of the antitumour T cell response in the context of immune checkpoint blockade, adoptive cell therapy and treatment with oncolytic viruses, and discuss emerging combination strategies.
引用
收藏
页码:785 / 797
页数:13
相关论文
共 50 条
  • [41] Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo, Alessandro
    Mollica, Veronica
    Cimadamore, Alessia
    Santoni, Matteo
    Scarpelli, Marina
    Giunchi, Francesca
    Cheng, Liang
    Lopez-Beltran, Antonio
    Fiorentino, Michelangelo
    Montironi, Rodolfo
    Massari, Francesco
    CELLS, 2020, 9 (09) : 1 - 24
  • [42] Curcumin as an Adjuvant to Cancer Immunotherapy
    Paul, Silpita
    Sa, Gaurisankar
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Releasing the Brakes on Cancer Immunotherapy
    Littman, Dan R.
    CELL, 2015, 162 (06) : 1186 - 1190
  • [44] Targeting neoantigens for cancer immunotherapy
    Lu, Yong-Chen
    Robbins, Paul F.
    INTERNATIONAL IMMUNOLOGY, 2016, 28 (07) : 365 - 370
  • [45] Acquired resistance to cancer immunotherapy
    Draghi, Arianna
    Chamberlain, Christopher Aled
    Furness, Andrew
    Donia, Marco
    SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (01) : 31 - 40
  • [46] Genomic determinants of cancer immunotherapy
    Miao, Diana
    Van Allen, Eliezer M.
    CURRENT OPINION IN IMMUNOLOGY, 2016, 41 : 32 - 38
  • [47] New insight into cancer immunotherapy
    Escribese, M. M.
    Barber, D.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2017, 45 : 50 - 55
  • [48] Cancer immunotherapy targeting neoantigens
    Lu, Yong-Chen
    Robbins, Paul F.
    SEMINARS IN IMMUNOLOGY, 2016, 28 (01) : 22 - 27
  • [49] Immunotherapy and immunoevasion of colorectal cancer
    Al Zein, Mohammad
    Boukhdoud, Mona
    Shammaa, Hadi
    Mouslem, Hadi
    El Ayoubi, Lemir Majed
    Iratni, Rabah
    Issa, Khodr
    Khachab, Maha
    Assi, Hazem I.
    Sahebkar, Amirhossein
    Eid, Ali H.
    DRUG DISCOVERY TODAY, 2023, 28 (09)
  • [50] Current Perspectives in Cancer Immunotherapy
    Christofi, Theodoulakis
    Baritaki, Stavroula
    Falzone, Luca
    Libra, Massimo
    Zaravinos, Apostolos
    CANCERS, 2019, 11 (10)